News | February 26, 2008

FDA Approves Three Products for Cardiac Rhythm Management

February 27, 2008 - Boston Scientific Corp. said the FDA approved three products in its Cardiac Rhythm Management business, including the CONFIENT implantable cardioverter defibrillator (ICD), the LIVIAN cardiac resynchronization therapy defibrillator (CRT-D) and an upgraded LATITUDE Patient Management System.

The CONFIENT ICD reportedly features an enhanced AV (atrial ventricular) Search Hysteresis designed to reduce unnecessary right ventricular pacing. The device is equipped with wireless capability designed to save physicians time during implant by allowing device programming during wound closure and eliminating the need for the programming wand in the sterile field. Wireless capability also saves time at follow-up visits by offering device interrogations that can be three times faster than the company’s wanded telemetry, said Boston Scientific.

The LIVIAN CRT-D reportedly enables physicians to provide patients with individualized therapy using SmartDelay technology which enables physicians to tailor individualized pacing therapies for their patients. The CRT-DA also used the Bi-V Trigger with ventricular rate regulation designed to help physicians manage heart failure patients with frequent atrial arrhythmias.

The upgraded LATITUDE Patient Management System reportedly has enhanced remote monitoring capabilities that include a new alert in the CONFIENT ICD that notifies physicians if a patient’s percentage of right ventricular pacing increases above a programmable threshold, and a new alert notifies physicians if a patient’s percentage of biventricular pacing falls below a programmable threshold.

Both the CONFIENT ICD and LIVIAN CRT-D are designed to allow physicians to manage their patients wirelessly on the LATITUDE Patient Management System.

For more information:

Related Content

Boston Scientific Launches Resonate Devices With HeartLogic Heart Failure Diagnostic
Technology | Implantable Cardioverter Defibrillator (ICD)| September 27, 2017
September 27, 2017 — Boston Scientific recently launched the Resonate family of...
Abbott Secures FDA Approval for MRI Compatibility on Ellipse ICD
Technology | Implantable Cardioverter Defibrillator (ICD)| September 22, 2017
Abbott announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for...
Predictive Models May Help Determine Which Patients Benefit From ICDs
News | Implantable Cardioverter Defibrillator (ICD)| July 06, 2017
Two predictive models may help cardiologists decide which patients would most benefit from an implantable cardioverter...
Videos | Implantable Cardioverter Defibrillator (ICD)| June 01, 2017
Lucas Boersma, M.D., Ph.D., FESC, St.
The Unify ICD is one of the SJM devices in an FDA warning letter
Feature | Implantable Cardioverter Defibrillator (ICD)| April 14, 2017 | Dave Fornell
April 14, 2017 — The U.S. Food and Drug Administration (FDA) sent a warning letter to Abbott/St.
ICDs, non-ischemic cardiomyopathy, University of Alabama at Birmingham study, Circulation
News | Implantable Cardioverter Defibrillator (ICD)| January 18, 2017
A new study published in Circulation has found there is a 23 percent risk in reduction of all-cause mortality in non-...
ICDs, implantable cardioverter defibrillators, survival rate, elderly patients, JACC study
News | Implantable Cardioverter Defibrillator (ICD)| January 17, 2017
Of patients over age 65 who received an implantable cardioverter-defibrillator (ICD) after surviving sudden cardiac...
Overlay Init